Gocatamig + Atezolizumab + Ifinatamab Deruxtecan (I-DXd)

Phase 1/2Active

0 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Small-Cell Lung Cancer

Conditions

Small-Cell Lung Cancer, Neuroendocrine Carcinoma

Trial Timeline

Dec 14, 2020 → Jan 28, 2028

NCT ID

NCT04471727

About Gocatamig + Atezolizumab + Ifinatamab Deruxtecan (I-DXd)

Gocatamig + Atezolizumab + Ifinatamab Deruxtecan (I-DXd) is a phase 1/2 stage product being developed by Daiichi Sankyo for Small-Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04471727. Target conditions include Small-Cell Lung Cancer, Neuroendocrine Carcinoma.

What happened to similar drugs?

7 of 20 similar drugs in Small-Cell Lung Cancer were approved

Approved (7) Terminated (7) Active (8)

✅Gefitinib + DocetaxelAstraZenecaApproved

✅PembrolizumabMerckApproved

✅zoledronic acidNovartisApproved

✅AtezolizumabRocheApproved

✅Erlotinib + ChemotherapyRocheApproved

✅LorlatinibPfizerApproved

✅Pemetrexed + ErlotinibHikma PharmaceuticalsApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04471727	Phase 1/2	Active	Dec 14, 2020	Jan 28, 2028	Small-Cell Lung Cancer

Competing Products

20 competing products in Small-Cell Lung Cancer

See all competitors

Product	Company	Stage	Hype Score
pemetrexed + erlotinib	Eli Lilly	Phase 2	35
6-Thio-2'-Deoxyguanosine + Cemiplimab	MAIA Biotechnology	Phase 2	32
pemetrexed + cisplatin	Eli Lilly	Phase 2	27
Cetuximab	Eli Lilly	Phase 1	29
LY2875358 + Erlotinib	Eli Lilly	Phase 2	35
Adjuvant	Insight Molecular Diagnostics	Pre-clinical	8
Enzastaurin HCL	Eli Lilly	Phase 2	35
CAB-AXL-ADC + PD-1 inhibitor	BioAtla	Phase 2	25
ALIMTA + Carboplatin	Eli Lilly	Phase 2	35
Lazertinib	Yuhan	Phase 1/2	32
Ifinatamab Deruxtecan (I-DXd)	Daiichi Sankyo	Phase 2	39
CS-7017 + Erlotinib	Daiichi Sankyo	Phase 1	29
Datopotamab Deruxtecan (Dato-DXd)	Daiichi Sankyo	Phase 1/2	36
Raludotatug Deruxtecan + Ifinatamab Deruxtecan + Docetetaxel + 5-hydroxytryptamine subtype 3 receptor antagonist + Neurokinin-1 receptor antagonist + Corticosteroid	Daiichi Sankyo	Phase 2	42
Pembrolizumab + Carboplatin + Paclitaxel + Pemetrexed + Vibostolimab + Boserolimab + MK-4830 + MK-0482 + Ifinatamab Deruxtecan (I-DXd) + HER3-DXd	Daiichi Sankyo	Phase 1/2	39
CS-7017 + Carboplatin + Paclitaxel	Daiichi Sankyo	Phase 1	29
Valemetostat + Atezolizumab	Daiichi Sankyo	Phase 1	36
Tivantinib + Placebo + Erlotinib	Daiichi Sankyo	Phase 3	32
Gilteritinib + Erlotinib	Astellas Pharma	Phase 1/2	24
naquotinib + midazolam	Astellas Pharma	Phase 1	29